ABSOLUTE PASI REDUCTIONS IN A PHASE 2B TRIAL OF THE SELECTIVE ORAL TYK2 INHIBITOR, TAK-279, IN MODERATE-TO-SEVERE PLAQUE PSORIASIS

被引：0
|
作者：
Green, Lawrence [1 ]
Ferris, Laura [2 ]
Moore, Angela [3 ,7 ,8 ]
Zirwas, Matthew [4 ]
Zhao, Yiwei [5 ]
Blau, Jessamyn [5 ]
Zhang, Wenwen [5 ]
Uy, Jonathan [5 ]
Winkelman, Warren [5 ]
Vender, Ronald [6 ]
机构：
[1] George Washington Univ, Sch Med, Rockville, MD USA
[2] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA
[3] Baylor Univ, Med Ctr, Dallas, TX USA
[4] Dermatologists Greater Columbus, Columbus, OH USA
[5] Takeda Dev Ctr Amer Inc, Cambridge, MA USA
[6] Dermatrials Res Inc, Hamilton, ON, Canada
[7] Arlington Res Ctr, Arlington, TX USA
[8] Arlington Ctr Dermatol, Arlington, TX USA
来源：
ACTA DERMATO-VENEREOLOGICA | 2024年 / 104卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P-069
引用
收藏
页数：102
相关论文
共 50 条
  • [21] Influence of Patient Baseline Characteristics on Zasocitinib (TAK-279) Efficacy, a Selective Oral Tyrosine Kinase 2 Inhibitor: A Randomized Phase 2b Trial in Psoriatic Arthritis
    Eder, Lihi
    Muensterman, Elena
    van der Heijde, Desiree
    Kivitz, Alan
    Trivedi, Mona
    Hong, Ting
    Rehman, Muhammad
    Weng, Haoling
    Chen, Jingjing
    Baraliakos, Xenofon
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 4718 - 4720
  • [22] Zasocitinib (TAK-279), a Highly Selective Oral Tyrosine Kinase 2 (TYK2) Inhibitor, Elicits Early Skin Responses and Minimal Disease Activity in Patients with Active Psoriatic Arthritis: Results from a Randomized Phase 2b Study
    Gottlieb, Alice
    Muensterman, Elena
    Kivitz, Alan
    Dokoupilova, Eva
    Lertratanakul, Apinya
    Hong, Ting
    Chen, Jingjing
    Baraliakos, Xenofon
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 3007 - 3011
  • [23] A phase 2b trial of baricitinib, an oral JAK inhibitor, in patients with moderate to severe psoriasis
    Menter, Alan
    Disch, Damon
    Clemens, Jeffrey
    Janes, Jonathan
    Papp, Kim
    Macias, William
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB162 - AB162
  • [24] Zasocitinib (TAK-279), an Oral, Selective Tyrosine Kinase 2 Inhibitor: Achievement of Remission and Additional Improvements in Disease Activity in Patients with Psoriatic Arthritis Enrolled in a Phase 2b Trial
    Mease, Philip
    Kivitz, Alan
    Muensterman, Elena
    Lertratanakul, Apinya
    Hong, Ting
    Chen, Jingjing
    Mark, Ejim
    Baraliakos, Xenofon
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 5247 - 5249
  • [25] INFLUENCE OF BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS ON EFFICACY OF AN ORAL, SELECTIVE TYK2 INHIBITOR, BMS-986165, IN PATIENTS WITH PLAQUE PSORIASIS IN A PHASE 2 TRIAL
    Gordon, Kenneth
    Papp, Kim
    Gooderham, Melinda
    Thaci, Diamant
    Foley, Peter
    Morita, Akimichi
    Kundu, Sudeep
    Kisa, Renata
    Napoli, Andrew
    Banerjee, Subhashis
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 907 - 908
  • [26] A selective inhibitor of TYK2, BMS-986165, improves molecular, cellular, and clinical biomarkers associated with efficacy in moderate-to-severe psoriasis
    Krueger, James
    Hu, Sarah
    Banerjee, Subhashis
    Gordon, Kenneth
    Catlett, Ian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB12 - AB12
  • [27] A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis
    Papp, K. A.
    Menter, M. A.
    Raman, M.
    Disch, D.
    Schlichting, D. E.
    Gaich, C.
    Macias, W.
    Zhang, X.
    Janes, J. M.
    BRITISH JOURNAL OF DERMATOLOGY, 2016, 174 (06) : 1266 - 1276
  • [28] A selective inhibitor of TYK2, BMS-986165, improves molecular, cellular, and clinical biomarkers associated with efficacy in moderate-to-severe psoriasis
    Catlett, I. M.
    Hu, S.
    Banerjee, S.
    Gordon, K.
    Krueger, J. G.
    EXPERIMENTAL DERMATOLOGY, 2018, 27 : 55 - 55
  • [29] Deucravacitinib, a selective tyrosine kinase 2 inhibitor, for the treatment of moderate-to-severe plaque psoriasis
    Galluzzo, Marco
    Vellucci, Laura
    Marcelli, Lorenzo
    Paganini, Claudia
    Bianchi, Luca
    Talamonti, Marina
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (09) : 981 - 988
  • [30] Analysis of histologic and molecular improvement in moderate-to-severe psoriasis: Results from a phase 1b trial of the novel allosteric Tyk2 inhibitor NTX-973
    McElwee, Joshua J.
    Garcet, Sandra
    Li, Xuan
    Cueto, Inna
    Kunjravia, Norma
    Rambhia, Darshna
    Srivastava, Bhaskar
    Krueger, James G.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB139 - AB139
12345